UK Community Advisory Board (UK-CAB)
Email | |
  • JOIN THE NETWORK

    • UK-CAB 30 – Testing

    31/07/2009 Alison Neathey
    Off
    Meetings

    Friday 31 July 2009

    Testing

    At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1

    Programme

    09:30 – 10:00 Registration, refreshments and expenses
    10:00 – 10:15 Welcome and UKCAB updates – Michael Marr
    10:15 –  11:00 BHIVA Routine Monitoring Guidelines – Matt Williams
    11:00 – 11:15 Break
    11:15 – 12:15 HIV Treatment Advocacy Overview

    • Definitions of advocacy – Michael Marr
    • History of advocacy film highlights
    • Advocacy Training in Practice – Winnie Sseruma
    12.15 – 12.30 Pre-Meeting for BMS – Simon Collins
    12:30 – 14:00 Lunch
    14:00 – 15:15 Company meeting: BMS
    15:15 – 15:30 Break
    15:30 – 16:00 Conference Feedback & UKCAB AOB – Simon Collins
    16:00 Close

    Background Reading

    Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment.
    Download as a PDF file [416 Kb]

    Denver Principles
    http://en.wikipedia.org/wiki/People_With_AIDS#The_Denver_Principles

    The Early AIDS Epidemic in the US: Views from Atlanta and Hollywood Harold Jaffe Univ of Oxford, UK
    http://www.retroconference.org/2008/data/files/retro2008_frameset.html

    Scottish Independent Advocacy Alliance
    http://www.siaa.org.uk/images/stories/siaaprinciples%26standardsforweb.pdf

    http://www.ncbi.nlm.nih.gov/pubmed/19496633?log$=activity

    http://www.hivinsite.com/insite?page=hmq-0810-04

    http://www.avert.org/aids-history-86.htm

    Financial support

    The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

    The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

    We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

    For a list of companies that support the UK-CAB please see the “about us” page.

    Meetings
    Meetings